Bayer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?
BAYER has one hundred and twenty-four approved drugs.
There are fifty-four US patents protecting BAYER drugs. There is one tentative approval on BAYER drugs.
There are one thousand one hundred and two patent family members on BAYER drugs in sixty countries and one hundred and ninety-eight supplementary protection certificates in twenty countries.
Summary for Bayer
International Patents: | 1102 |
US Patents: | 54 |
Tradenames: | 109 |
Ingredients: | 73 |
NDAs: | 124 |
Patent Litigation for Bayer: | See patent lawsuits for Bayer |
Drugs and US Patents for Bayer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | CLIMARA | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 020375-003 | Mar 23, 1998 | AB2 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Hlthcare | CHILDREN'S ASTEPRO ALLERGY | azelastine hydrochloride | SPRAY, METERED;NASAL | 213872-002 | Jun 17, 2021 | OTC | Yes | Yes | 9,919,050 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bayer | MIDOL | ibuprofen | TABLET;ORAL | 071001-001 | Sep 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 021037-001 | Mar 10, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Healthcare Llc | GYNE-LOTRIMIN 3 | clotrimazole | CREAM;VAGINAL | 020574-001 | Nov 24, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Pharms | MEZLIN | mezlocillin sodium monohydrate | INJECTABLE;INJECTION | 062333-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Pharms | STILPHOSTROL | diethylstilbestrol diphosphate | INJECTABLE;INJECTION | 010010-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer
Paragraph IV (Patent) Challenges for BAYER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
International Patents for Bayer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | PI0919071 | ⤷ Try a Trial |
Hong Kong | 1113310 | ⤷ Try a Trial |
Slovenia | 2725028 | ⤷ Try a Trial |
Japan | 2013100302 | ⤷ Try a Trial |
Serbia | 56045 | ⤷ Try a Trial |
Japan | 2019511575 | ⤷ Try a Trial |
Brazil | PI0919873 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663978 | 122013000086 | Germany | ⤷ Try a Trial | PRODUCT NAME: REGORAFENIB ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/858 20130826 |
2782584 | LUC00245 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
0984957 | PA2011005 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 |
3106463 | LUC00150 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
1506193 | 14C0032 | France | ⤷ Try a Trial | PRODUCT NAME: RIOCIGUAT,SES SELS,SES ISOMERES ET SES HYDRATES.; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327 |
1380301 | 2009C/007 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
2782584 | C202130068 | Spain | ⤷ Try a Trial | PRODUCT NAME: COMPOSICION QUE CONTIENE ESTRADIOL (17BETA-ESTRADIOL), INCLUYENDO EN FORMA DE HEMIHIDRATO, Y PROGESTERONA; NATIONAL AUTHORISATION NUMBER: 85988-NL/H/4994/001/DC; DATE OF AUTHORISATION: 20210528; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): BE582231; DATE OF FIRST AUTHORISATION IN EEA: 20210406 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.